<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520127</url>
  </required_header>
  <id_info>
    <org_study_id>63-10-2356</org_study_id>
    <nct_id>NCT03520127</nct_id>
  </id_info>
  <brief_title>A Registry Study Evaluating Outcomes in Breast Biopsy With the Intact™ Breast Lesion Excision System (BLES)</brief_title>
  <official_title>A Multi-center Registry Study Evaluating Outcomes in Breast Biopsy With the Intact™ Breast Lesion Excision System (BLES)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Surgical Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Surgical Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry study is to collect use and clinical outcomes data following
      breast lesion excision or sampling with the Intact BLES.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Product withdrawn from the market due to a shift in sponsor business focus
  </why_stopped>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Actual">February 28, 2019</completion_date>
  <primary_completion_date type="Actual">February 15, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Lesion BIRADS score</measure>
    <time_frame>Weeks prior to the Intact procedure</time_frame>
    <description>Diagnostic imaging result</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Imaging lesion size</measure>
    <time_frame>Weeks prior to the Intact procedure</time_frame>
    <description>Measured in mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion histology</measure>
    <time_frame>Weeks prior to the Intact procedure</time_frame>
    <description>Lesion biopsy results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissue margin (as reported from histology) rate</measure>
    <time_frame>Weeks after the Intact procedure, up to approximately 12 weeks</time_frame>
    <description>Procedure margin vs. margin size, measured in mm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Underestimation rate</measure>
    <time_frame>Weeks after the Intact procedure, up to approximately 12 weeks</time_frame>
    <description>Compared to maximum lesion size, measured in mm</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">176</enrollment>
  <condition>Breast Lesions</condition>
  <arm_group>
    <arm_group_label>Females, 18 years of age or older</arm_group_label>
    <description>Females, 18 years of age or older, who will undergo the Intact procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intact Breast Lesion Excision System (BLES)</intervention_name>
    <description>Intact BLES is an automated, percutaneous biopsy device capable of delivering a surgical quality specimen for histological review of breast abnormalities. It is uniquely suited to maintain lesion architecture within the biopsy sample, providing an opportunity for pathological assessment and the potential avoidance of an open surgical procedure.</description>
    <arm_group_label>Females, 18 years of age or older</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have undergone the Intact procedure that are female and 18 years of age or
        older.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Age ≥ 18 years

          -  BIRADS ≤ 5, as initially imaged

          -  Subject is willing and capable of providing informed consent and has a scheduled or
             planned breast lesion excision or sampling where the Intact BLES is expected to be
             used

        Exclusion Criteria:

          -  Male

          -  Subjects with subglandular (pre-pectoral, or &quot;single plane&quot;) breast implants

          -  Subjects with electronic implantable devices (such as pacemakers and defibrillators)

          -  Subjects who are contraindicated for surgery due to factors such as anti-coagulant use
             which cannot be safely reversed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lydia Sakakeeny, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic Surgical Technologies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Breast Care</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute-Emory St. Joseph's</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalton Surgical Group</name>
      <address>
        <city>Dalton</city>
        <state>Georgia</state>
        <zip>30720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Surgical Associates Inc.</name>
      <address>
        <city>Lithonia</city>
        <state>Georgia</state>
        <zip>30058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holyoke Medical Center</name>
      <address>
        <city>Holyoke</city>
        <state>Massachusetts</state>
        <zip>01040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Breast Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Breast Center at Chesapeake Regional Healthcare</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

